Trial reportIndian journal of pediatrics2022
Oral Application of Colostrum and Mother's Own Milk in Preterm Infants-A Randomized, Controlled Trial.
Trial report in Indian journal of pediatrics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 26 citations in OpenAlex.
- Effects of oropharyngeal administration of own mother's milk on oral microbial colonization in very low birth weight infants fed by gastric tube: A randomized controlled trial.Immunity, inflammation and disease · 2024Trial
- The effect of oropharyngeal mother's milk on nutritional outcomes in preterm infants: a randomized controlled trial.BMC pediatrics · 2024Trial
- A Prospective-Retrospective Observational Cohort Study of Short-Term Health Outcomes of Preterm Very Low Birth Weight Infants Receiving Oropharyngeal Administration of Own Mother's Colostrum.Current therapeutic research, clinical and experimental · 2026Article
- Synergistic regulation of gut microbiota and metabolites by breast milk and probiotics in the prevention of neonatal necrotizing enterocolitis: mechanisms and prospects.Translational pediatrics · 2026Review
- Application Effect of Colostrum Oral Immunotherapy in the Early Stage of Mechanical Ventilation for Very Low Birth Weight Preterm Infants.Journal of multidisciplinary healthcare · 2026Article
- Influence of oropharyngeal therapy with mother's own milk on the microbiome and metabolome of very preterm infants: a pilot study.Frontiers in nutrition · 2025Article
- The immunoregulatory role of gut microbiota in the incidence, progression, and therapy of breast cancer.Frontiers in cellular and infection microbiology · 2024Review
- The Effect of Holder Pasteurization and Different Variants on Breast Milk Antioxidants.Antioxidants (Basel, Switzerland) · 2023Article
- Colostrum and Preterm Babies: A Systematic Review.Cureus · 2023Review
- Prevention of Chronic Morbidities in Extremely Premature Newborns with LISA-nCPAP Respiratory Therapy and Adjuvant Perinatal Strategies.Antioxidants (Basel, Switzerland) · 2023Review
- Oral Application of Mother's Own Milk for Reducing Necrotizing Enterocolitis in Preterm Infants: An Updated Meta-Analysis of RCTs.Evidence-based complementary and alternative medicine : eCAM · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo evaluate the effects of oral application of mother's own milk (OMOM) on clinical outcomes in preterm infants of 26
methodsIn this placebo-controlled randomized trial, subjects received either OMOM or sterile water, beginning at 24-72 h of life, until the infant reached 32 wk postmenstrual age or spoon-feeds were initiated, whichever was earlier. The primary outcome was a composite adverse health outcome, defined as the occurrence of either mortality, late-onset sepsis (LOS), necrotizing enterocolitis (NEC), intraventricular hemorrhage (IVH), bronchopulmonary dysplasia (BPD), or retinopathy of prematurity (ROP). Antibiotic usage and time to full enteral feed were secondary outcomes. Salivary IgA (sIgA) levels at baseline and after 7 d of application in a subset of infants were also compared.
resultsA total of 133 neonates (66 colostrum and 67 placebo) were analyzed for the primary outcome. OMOM group had lower incidence of composite adverse health outcome (43.9% vs. 61.2%, RR: 0.70; 95% CI: 0.50-0.99, p = 0.046) and LOS (22.7% vs. 43.3%, RR: 0.73; 95% CI: 0.57-0.93; p = 0.012). There were no significant differences in mortality, NEC, IVH, BPD, ROP, and time to full feeds. The effects were more pronounced in the 29
conclusionsOMOM decreases the incidence of late-onset sepsis in preterm neonates (26
trial registrationClinical Trials Registry-India CTRI/2017/03/008031.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.